EVH
$2.83
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States.
Intraday
Recent News
3 Unprofitable Stocks We Approach with Caution
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
How The Evolent Health (EVH) Investment Story Is Shifting After Reserves Reset And Higher Leverage
Evolent Health’s latest analyst update centers on a reset in price expectations, with a model fair value estimate moving from US$8.50 to US$5.18 and aligning more closely with targets clustered in the mid single digits. Analysts link this shift to renewed attention on reserves, leverage and margin visibility, with views split between seeing conservative reserving and new contracts as supportive, and worrying about higher debt and medical cost pressures. As you read on, you will see how these...
AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
Privia Health Expands Value Based Care Scale With Evolent ACO Acquisition
Privia Health Group (NasdaqGS:PRVA) has acquired Evolent Health's accountable care organization business. The deal brings over 120,000 new attributed lives into Privia's value based care model. The acquisition coincides with Privia's continued entry into new states, including Arizona. Privia Health Group, trading at around $23.75 a share, is trying to build scale in value based care. This transaction meaningfully increases the number of patients tied to its model. The stock is up 8.0% over...
Privia Health Group (PRVA) Is Up 8.0% After Raising 2026 Revenue Guidance and Beating Q4 Targets
In late February 2026, Privia Health Group reported fourth-quarter 2025 results showing US$541.17 million in sales and US$9.15 million in net income, alongside full-year 2025 revenue of US$2.12 billion and new 2026 GAAP revenue guidance of US$2.35 billion to US$2.45 billion. Beyond beating analyst forecasts, Privia highlighted expanding provider relationships, successful integration of Evolent Health’s ACO business, and strong cash generation, underlining the scale of its value-based care...